AnalystsMichael LeuchtenMichael Leuchten's Stock Forecasts
AnalystsMichael Leuchten
Sectors:
Industries:
Analyst Ranking
Bottom 50%
#2784 out of 5515 analysts
Average Return
+2.54%
Win Rate
67%4 out of 6
Risk vs Reward
Poor
Good
Michael Leuchten's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Astrazeneca PLCAZN | +23.86% | $97.82 | $121.16 | 2021-02-25 - 2022-02-25 | Strong Buy |
Novo Nordisk A SNVO | +18.25% | $52.89 | $43.24 | 2025-10-27 - 2026-09-18 | Sell |
Gsk PLCGSK | +14.66% | $43.80 | $50.22 | 2025-10-27 - 2026-09-18 | Strong Buy |
SanofiSNY | +4.85% | $43.74 | $41.62 | 2018-01-23 - 2019-01-23 | Strong Sell |
Michael Leuchten Analyst Color
Get additional color on Michael Leuchten's coverage of popular stocks
Michael Leuchten's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Novo Nordisk A SNVO | 2 | Sell | N/A | N/A | Assumes | a year ago |
Novartis AgNVS | 1 | Hold | N/A | N/A | Assumes | a year ago |
Gsk PLCGSK | 1 | Strong Buy | N/A | N/A | Assumes | a year ago |
Astrazeneca PLCAZN | 2 | Strong Buy | N/A | N/A | Assumes | a year ago |
SanofiSNY | 1 | Strong Sell | N/A | N/A | Downgrades | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.